Inhibitor of nuclear factor kappa-B kinase (IKK)

The Inhibitor of nuclear factor kappa-B kinase (IKK) is a multi-subunit enzyme complex that serves as the master regulator of the NF-κB signaling pathway, a critical mediator of inflammation and immune responses. The complex typically consists of two catalytic subunits, IKKα and IKKβ, and a regulatory subunit, IKKγ (NEMO). Upon activation by various stimuli such as cytokines (TNF-α, IL-1) or microbial products, the IKK complex phosphorylates IκB proteins, marking them for proteasomal degradation and allowing NF-κB transcription factors to enter the nucleus and activate genes involved in cell survival and inflammation (Source: UniProt, P78527; PubMed: 10485830). Dysregulation of IKK activity is strongly linked to chronic inflammatory diseases and the progression of various cancers, where it promotes tumor cell proliferation and resistance to apoptosis. Consequently, IKK has been a high-priority therapeutic target for the development of anti-inflammatory and anti-cancer drugs. However, because the NF-κB pathway is essential for normal immune function and cell homeostasis, clinical development of IKK inhibitors has faced significant challenges regarding systemic toxicity and immunosuppression (Source: StatPearls, NF-kappa B; PubMed: 22460726).

Other names

I-kappa-B kinase complexIKK complexConserved helix-loop-helix ubiquitous kinase (CHUK)Inhibitor of nuclear factor kappa-B kinase subunit alpha (IKK-alpha)Inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-beta)Inhibitor of nuclear factor kappa-B kinase subunit gamma (IKK-gamma)NF-kappa-B essential modulator (NEMO)

Inhibition of the phosphorylation of IκB proteins (specifically IκBα), which prevents their subsequent ubiquitination and degradation, thereby sequestering NF-κB in the cytoplasm and preventing its nuclear translocation and transcriptional activity.